Novel Methods of Insulin Replacement: The Artificial Pancreas and Encapsulated Islets
Type 1 diabetes represents 5-10% of patients with diabetes worldwide. The importance of tight glycemic control has been demonstrated definitively in the Diabetes Control and Complications Trial but is often elusive for patients because of the associated risk of hypoglycemia. Care for
these patients requires coordination amongst a variety of health professionals including primary care providers, endocrinologists, nephrologists, ophthalmologists, pharmacists, podiatrists and others. The 21st century is witnessing emerging and exciting treatment options for this disease.
Previous attempts at curative therapy have included pancreas or islet transplantation, but limitations of organ availability and the risk associated with immunosuppression have resulted in renewed efforts for novel methods of insulin replacement. Advancement in technology has resulted in several
versions of an artificial pancreas—technology that uses a continuous glucose monitor to sense the blood sugar, transmit those numbers to a control algorithm that then doses insulin ± glucagon in response to changes in blood sugar. Free living experiments with two versions of the
artificial pancreas have recently been published. A quest for a bioartificial pancreas has been ongoing as well. In this system, islets (porcine, human, or embryonic stem cell derived) are encapsulated in a biocompatible device that is either a macrocapsule or a microcapsule. The benefits
of this system allows for replacement therapy without immunosuppression. Human trials with encapsulation are currently ongoing. This review will provide a detailed review of artificial and bioartificial pancreas systems with a focus on human trials.
Keywords: Artificial pancreas; bioartificial pancreas; bionic pancreas; encapsulated islets
Document Type: Research Article
Publication date: 01 June 2016
- Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I - IV clinical trial studies, clinical investigations at all stages of development and therapeutics.
The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content